Biocon recalibrates insulin strategy amid global shift toward GLP-1 therapies.

: Core insulin portfolio facing demand shifts : Exposure to diabetes therapies : Active in metabolic treatment markets Biocon is adapting its insulin strategy as newer GLP-1 drugs gain traction in diabetes care, altering treatment patterns and demand dynamics. Neutral to cautious: therapy innovation can disrupt legacy products; investors track pipeline strength, market shifts, and regulatory pathways. Healthcare evolves rapidly; portfolio adaptability remains critical.